{"id":618618,"date":"2022-09-27T16:20:02","date_gmt":"2022-09-27T16:20:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=618618"},"modified":"2022-09-27T16:20:02","modified_gmt":"2022-09-27T16:20:02","slug":"type-2-diabetes-pipeline-assessment-2022-insights-into-the-emerging-drugs-latest-fda-and-ema-approvals-clinical-trials-and-treatment-outlook-lexicon-pharma-oramed-pharma-eli-lily-hanmi","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/type-2-diabetes-pipeline-assessment-2022-insights-into-the-emerging-drugs-latest-fda-and-ema-approvals-clinical-trials-and-treatment-outlook-lexicon-pharma-oramed-pharma-eli-lily-hanmi_618618.html","title":{"rendered":"Type 2 Diabetes Pipeline Assessment, 2022 | Insights into the Emerging Drugs, Latest FDA and EMA Approvals, Clinical Trials, and Treatment Outlook | Lexicon Pharma, Oramed Pharma, Eli Lily, Hanmi"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Type 2 Diabetes Pipeline Assessment, 2022 | Insights into the Emerging Drugs, Latest FDA and EMA Approvals, Clinical Trials, and Treatment Outlook | Lexicon Pharma, Oramed Pharma, Eli Lily, Hanmi\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Type 2 Diabetes Pipeline Assessment, 2022 | Insights into the Emerging Drugs, Latest FDA and EMA Approvals, Clinical Trials, and Treatment Outlook | Lexicon Pharma, Oramed Pharma, Eli Lily, Hanmi\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Type 2 Diabetes therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Type 2 Diabetes Pipeline Insight, 2022<\/strong>&#8221; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the&nbsp; Type 2 Diabetes Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Type 2 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Type 2 Diabetes Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/6aad05aae369e16f99e1cb71414507b5.jpg\" alt=\"Type 2 Diabetes Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Type 2 Diabetes Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about emerging therapies for the <strong>treatment of Type 2 Diabetes<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for <strong>Type 2 Diabetes Treatment.<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the<strong> Type 2 Diabetes market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Type 2 Diabetes Therapeutic Segment:<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight&rsquo;s Report covers around 100+ products under different phases of clinical development like<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Early-stage product (Phase I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 2 Diabetes Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Globally, there are approx. <strong>100+ key companies<\/strong> which are developing therapies for Type 2 Diabetes.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Type 2 Diabetes Therapeutics Market include<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Hanmi Pharmaceuticals, Sanofi, Eli Lily and Company, AstraZeneca, NovoNordisk,&nbsp; Noxxon Pharma AG, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Daiichi Sankyo Company, Halozyme Therapeutics, Saniona, Novartis, Pfizer, Merck Sharp &amp; Dohme Corp., Mylan, Nordic Bioscience A\/S, KeyBioscience AG,&nbsp; Adocia, Jiangsu Hengrui Medicine, Bristol Myers Squibb, Phenomix, Forest Laboratories, ACADIA Pharmaceuticals, Hanmi Pharmaceuticals, Cytogel, Ligand Pharmaceuticals,&nbsp; Arthritis Innovation Corporation, Astellas Pharma, IItoo Pharma, Medspace Inc., Oramed Ltd., Flexion Therapeutics, Integrium, AbbVie<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Type 2 Diabetes Emerging Drugs Covered in the report include:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; Sotagliflozin: Lexicon Pharmaceuticals&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; ORMD0801: Oramed Pharmaceuticals&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; LY3209590: Eli Lily and Company<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; HM12460A: Hanmi Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&bull; HM14220: Hanmi Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Type 2 Diabetes Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Type 2 Diabetes &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Type 2 Diabetes Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Type 2 Diabetes Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Type 2 Diabetes Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Type 2 Diabetes Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Type 2 Diabetes Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Type 2 Diabetes Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Type 2 Diabetes Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Type 2 Diabetes Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Type 2 Diabetes Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Type 2 Diabetes Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/type-2-diabetes-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/tumor-ablation-market\">Tumor Ablation Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;Tumor Ablation Market&rdquo; research report provides a detailed overview of the historical and forecasted epidemiology as well as the Tumor Ablation Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=type-2-diabetes-pipeline-assessment-2022-insights-into-the-emerging-drugs-latest-fda-and-ema-approvals-clinical-trials-and-treatment-outlook-lexicon-pharma-oramed-pharma-eli-lily-hanmi\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=type-2-diabetes-pipeline-assessment-2022-insights-into-the-emerging-drugs-latest-fda-and-ema-approvals-clinical-trials-and-treatment-outlook-lexicon-pharma-oramed-pharma-eli-lily-hanmi\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Type 2 Diabetes therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/type-2-diabetes-pipeline-assessment-2022-insights-into-the-emerging-drugs-latest-fda-and-ema-approvals-clinical-trials-and-treatment-outlook-lexicon-pharma-oramed-pharma-eli-lily-hanmi_618618.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,425,426,404],"tags":[],"class_list":["post-618618","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Finance","category-Financial-Market","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/618618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=618618"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/618618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=618618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=618618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=618618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}